Literature DB >> 8164443

Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data.

H A Austin1, D T Boumpas, E M Vaughan, J E Balow.   

Abstract

Despite several years of intense investigation, there continues to be controversy about the value of clinical, demographic and histologic features in prediction of outcomes of lupus nephritis. In addition, contemporary treatments have reduced the risk of progressive renal injury and thus may have altered the prognostic significance of some of these factors. We have therefore re-examined the predictive value of variables previously associated with an increased risk of renal insufficiency by studying 65 patients with severe lupus nephritis treated with intensive regimens of intravenous pulse cyclophosphamide or methylprednisolone. Five clinical features at study entry were each associated with an increased probability of doubling the serum creatinine: age greater than 30 years, Black race, hematocrit less than 26%, serum creatinine greater than 2.4 mg/dl, and C3 complement less than 76 mg/dl. By multivariate survival analysis, serum creatinine, hematocrit and race emerged as the strongest set of independent clinical predictors; the other clinical and demographic factors, including age and C3 complement did not contribute significantly to outcome predictions in the context of these three variables. Renal biopsy evaluation offered additional prognostic information and showed that patients with severe active and chronic histologic changes were at increased risk for developing renal insufficiency. The combination of cellular crescents and interstitial fibrosis was particularly ominous. Outcome predictions based on the strongest clinical model (serum creatinine, hematocrit and race) were significantly enhanced by the addition of renal pathology data. Consideration of these prognostic factors may contribute to decisions regarding the type and intensity of immunosuppressive therapy for patients with lupus nephritis.

Entities:  

Mesh:

Year:  1994        PMID: 8164443     DOI: 10.1038/ki.1994.70

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  80 in total

1.  Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes.

Authors:  Catharina M Haring; Anke Rietveld; Jan A J G van den Brand; Jo H M Berden
Journal:  J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 10.121

2.  In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis.

Authors:  Anthony Chang; Scott G Henderson; Daniel Brandt; Ni Liu; Riteesha Guttikonda; Christine Hsieh; Natasha Kaverina; Tammy O Utset; Shane M Meehan; Richard J Quigg; Eric Meffre; Marcus R Clark
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

3.  Conference report--lupus nephritis: diagnosis, therapy, and outcomes.

Authors:  Sara M Mariani
Journal:  MedGenMed       Date:  2004-07-02

4.  T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis.

Authors:  Robert A Cohen; George Bayliss; Jose C Crispin; Gwen F Kane-Wanger; Christine A Van Beek; Vasileios C Kyttaris; Ingrid Avalos; C Yung Yu; George C Tsokos; Isaac E Stillman
Journal:  Clin Immunol       Date:  2008-07       Impact factor: 3.969

5.  Lupus or syphilis? That is the question!

Authors:  Joana Azevedo Duarte; Celia Coelho Henriques; Carolina Sousa; José Delgado Alves
Journal:  BMJ Case Rep       Date:  2015-06-04

6.  Histopathological indicators of disease outcome in class IV lupus nephritis: a revisit of various indices.

Authors:  Manish Rathi; Krishan Lal Gupta; Kusum Joshi; Pramod K Gupta; Aman Sharma; Harbir Singh Kohli; Vivekanand Jha; Vinay Sakhuja
Journal:  Rheumatol Int       Date:  2015-03-11       Impact factor: 2.631

7.  Autoantibodies against C-Reactive Protein Influence Complement Activation and Clinical Course in Lupus Nephritis.

Authors:  Qiu-Yu Li; Hai-Yun Li; Ge Fu; Feng Yu; Yi Wu; Ming-Hui Zhao
Journal:  J Am Soc Nephrol       Date:  2017-05-31       Impact factor: 10.121

8.  Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

Authors:  Howard A Austin; Gabor G Illei; Michelle J Braun; James E Balow
Journal:  J Am Soc Nephrol       Date:  2009-03-18       Impact factor: 10.121

Review 9.  The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis.

Authors:  Marcus R Clark; Kimberly Trotter; Anthony Chang
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

10.  Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys.

Authors:  José C Crispín; Mohamed Oukka; George Bayliss; Robert A Cohen; Christine A Van Beek; Isaac E Stillman; Vasileios C Kyttaris; Yuang-Taung Juang; George C Tsokos
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.